Literature DB >> 32167560

Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer.

John D Groarke1,2, David L Payne1, Brian Claggett1, Mandeep R Mehra1, Jingyi Gong1, Jesse Caron1, Syed S Mahmood3, Jon Hainer4, Tomas G Neilan5, Ann H Partridge2, Marcelo Di Carli4, Lee W Jones3, Anju Nohria1,2.   

Abstract

AIMS: The prognostic importance of post-diagnosis assessment of cardiorespiratory fitness (CRF) in cancer patients is not well established. We sought to examine the association between CRF and mortality in cancer patients. METHODS AND
RESULTS: This was a single-centre cohort analysis of 1632 patients (58% male; 64 ± 12 years) with adult-onset cancer who were clinically referred for exercise treadmill testing a median of 7 [interquartile range (IQR): 3-12] years after primary diagnosis. Cardiorespiratory fitness was defined as peak metabolic equivalents (METs) achieved during standard Bruce protocol and categorized by tertiles. The association between CRF and all-cause and cause-specific mortality was assessed using multivariable Cox proportional hazard models adjusting for important covariates. Median follow-up was 4.6 (IQR: 2.6-7.0) years; a total of 411 deaths (229, 50, and 132 all-cause, cardiovascular (CV), and cancer related, respectively) occurred during this period. Compared with low CRF (range: 1.9-7.6 METs), the adjusted hazard ratio (HR) for all-cause mortality was 0.38 [95% confidence interval (CI): 0.28-0.52] for intermediate CRF (range: 7.7-10.6 METs) and 0.17 (95% CI: 0.11-0.27) for high CRF (range: 10.7-22.0 METs). The corresponding HRs were 0.40 (95% CI: 0.19-0.86) and 0.41 (95% CI: 0.16-1.05) for CV mortality and 0.40 (95% CI: 0.26-0.60) and 0.16 (95% CI: 0.09-0.28) for cancer mortality, respectively. The adjusted risk of all-cause, CV, and cancer mortality decreased by 26%, 14%, and 25%, respectively with each one MET increment in CRF.
CONCLUSION: Cardiorespiratory fitness is a strong, independent predictor of all-cause, CV, and cancer mortality, even after adjustment for important clinical covariates in patients with certain cancers. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cancer; Cancer mortality; Cardiac rehab; Cardio-oncology; Cardiorespiratory fitness; Cardiovascular mortality; Cause-specific mortality; Exercise; Mortality

Mesh:

Year:  2020        PMID: 32167560     DOI: 10.1093/ehjqcco/qcaa015

Source DB:  PubMed          Journal:  Eur Heart J Qual Care Clin Outcomes        ISSN: 2058-1742


  11 in total

1.  Performance Status in Cancer: Not Broken, But Time for an Upgrade?

Authors:  Jessica M Scott; Guro Stene; Elisabeth Edvardsen; Lee W Jones
Journal:  J Clin Oncol       Date:  2020-06-25       Impact factor: 44.544

2.  Validity of Estimated Cardiorespiratory Fitness in Patients With Primary Breast Cancer.

Authors:  Meghan Michalski; Kylie Rowed; Jessica A Lavery; Chaya S Moskowitz; Catherine Capaci; Guro Stene; Elisabeth Edvardsen; Neil D Eves; Lee W Jones; Jessica M Scott
Journal:  JACC CardioOncol       Date:  2022-06-21

3.  Can We Estimate Cardiorespiratory Fitness in Breast Cancer Survivors Without Exercise?

Authors:  Daniel A Zlotoff; Matthew Nayor
Journal:  JACC CardioOncol       Date:  2021-12-21

Review 4.  The cancer patient and cardiology.

Authors:  José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti
Journal:  Eur J Heart Fail       Date:  2020-10-02       Impact factor: 15.534

5.  A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).

Authors:  Michael R Harrison; Paul G Davis; Michel G Khouri; David B Bartlett; Rajan T Gupta; Andrew J Armstrong; Megan A McNamara; Tian Zhang; Monika Anand; Kelly Onyenwoke; Sara Edwardson; Danielle Craig; Meghan Michalski; Yuan Wu; Taofik Oyekunle; Brian Coyne; Aubrie Coburn; Lee W Jones; Daniel J George
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-10       Impact factor: 5.554

6.  Skeletal muscle mitochondrial dysfunction and muscle and whole body functional deficits in cancer patients with weight loss.

Authors:  Hawley E Kunz; John D Port; Kenton R Kaufman; Aminah Jatoi; Corey R Hart; Kevin J Gries; Ian R Lanza; Rajiv Kumar
Journal:  J Appl Physiol (1985)       Date:  2021-12-23

7.  Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy.

Authors:  Alis Bonsignore; Thomas H Marwick; Scott C Adams; Babitha Thampinathan; Emily Somerset; Eitan Amir; Mike Walker; Husam Abdel-Qadir; C Anne Koch; Heather J Ross; Anna Woo; Bernd J Wintersperger; Mark J Haykowsky; Paaladinesh Thavendiranathan
Journal:  JACC CardioOncol       Date:  2021-11-16

8.  Vo2peak in Adult Survivors of Hodgkin Lymphoma: Rate of Decline, Sex Differences, and Cardiovascular Events.

Authors:  Raheel Rizwan; Kimberlee Gauvreau; Cheryl Vinograd; Jessica M Yamada; Christina Mangano; Andrea K Ng; Mark E Alexander; Ming Hui Chen
Journal:  JACC CardioOncol       Date:  2021-06-15

9.  Exercise Testing in Those Treated for Breast Cancer: Can One Forecast Peak Oxygen Consumption?

Authors:  Carl J Ade; Ryan Broxterman; W Gregory Hundley
Journal:  JACC CardioOncol       Date:  2022-06-21

Review 10.  Young Adult Cancer Survivorship: Recommendations for Patient Follow-up, Exercise Therapy, and Research.

Authors:  Scott C Adams; Jennifer Herman; Iliana C Lega; Laura Mitchell; David Hodgson; Kim Edelstein; Lois B Travis; Catherine M Sabiston; Paaladinesh Thavendiranathan; Abha A Gupta
Journal:  JNCI Cancer Spectr       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.